JP2011501656A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011501656A5 JP2011501656A5 JP2010527128A JP2010527128A JP2011501656A5 JP 2011501656 A5 JP2011501656 A5 JP 2011501656A5 JP 2010527128 A JP2010527128 A JP 2010527128A JP 2010527128 A JP2010527128 A JP 2010527128A JP 2011501656 A5 JP2011501656 A5 JP 2011501656A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- sequence
- seq
- chain variable
- variable domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 8
- 239000005557 antagonist Substances 0.000 claims 8
- 238000006467 substitution reaction Methods 0.000 claims 5
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000033115 angiogenesis Effects 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 230000008728 vascular permeability Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 229960000397 bevacizumab Drugs 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102220499814 Carbonic anhydrase 2_N62A_mutation Human genes 0.000 claims 1
- 238000012286 ELISA Assay Methods 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102220536901 PRKC apoptosis WT1 regulator protein_L69I_mutation Human genes 0.000 claims 1
- 102220480127 Protein-tyrosine sulfotransferase 1_N60A_mutation Human genes 0.000 claims 1
- 102220494895 Stromal cell-derived factor 2-like protein 1_T46L_mutation Human genes 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 102000058223 human VEGFA Human genes 0.000 claims 1
- 230000002055 immunohistochemical effect Effects 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 102200094891 rs121913566 Human genes 0.000 claims 1
- 102200074783 rs144422014 Human genes 0.000 claims 1
- 102220008795 rs193922245 Human genes 0.000 claims 1
- 102200096229 rs387906796 Human genes 0.000 claims 1
- 102220040412 rs587778307 Human genes 0.000 claims 1
- 102200124875 rs59151893 Human genes 0.000 claims 1
- 102200153731 rs7122277 Human genes 0.000 claims 1
- 102220061206 rs786203134 Human genes 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97547107P | 2007-09-26 | 2007-09-26 | |
| PCT/US2008/077622 WO2009042746A1 (en) | 2007-09-26 | 2008-09-25 | Novel antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011501656A JP2011501656A (ja) | 2011-01-13 |
| JP2011501656A5 true JP2011501656A5 (enExample) | 2011-11-10 |
Family
ID=40329277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010527128A Pending JP2011501656A (ja) | 2007-09-26 | 2008-09-25 | 新規抗体 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US7973138B2 (enExample) |
| EP (1) | EP2200700B1 (enExample) |
| JP (1) | JP2011501656A (enExample) |
| KR (1) | KR20100065162A (enExample) |
| CN (1) | CN101888878B (enExample) |
| AR (1) | AR066170A1 (enExample) |
| AU (1) | AU2008304452B2 (enExample) |
| BR (1) | BRPI0816049A2 (enExample) |
| CA (1) | CA2698609A1 (enExample) |
| CL (1) | CL2008002856A1 (enExample) |
| CO (1) | CO6260094A2 (enExample) |
| DK (1) | DK2200700T3 (enExample) |
| HR (1) | HRP20160308T1 (enExample) |
| HU (1) | HUE027911T2 (enExample) |
| MX (1) | MX2010003325A (enExample) |
| MY (1) | MY151191A (enExample) |
| NZ (1) | NZ584838A (enExample) |
| PE (1) | PE20091029A1 (enExample) |
| RU (1) | RU2490277C2 (enExample) |
| SI (1) | SI2200700T1 (enExample) |
| TW (1) | TWI547503B (enExample) |
| WO (1) | WO2009042746A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008304452B2 (en) | 2007-09-26 | 2014-01-16 | Genentech, Inc. | Novel antibodies |
| RU2011142974A (ru) | 2009-03-25 | 2013-04-27 | Дженентек, Инк. | НОВЫЕ АНТИТЕЛА ПРОТИВ α5β1 И ИХ ПРИМЕНЕНИЕ |
| CA2665956A1 (en) * | 2009-05-07 | 2010-11-07 | Samir Patel | Combination treatment for ocular diseases |
| US8404811B2 (en) | 2009-05-08 | 2013-03-26 | Genentech, Inc. | Humanized anti-EGFL7 antibodies and methods using same |
| US8956600B2 (en) | 2009-08-10 | 2015-02-17 | Taiwan Liposome Co. Ltd. | Ophthalmic drug delivery system containing phospholipid and cholesterol |
| US8852592B2 (en) | 2011-05-10 | 2014-10-07 | Biocare Medical, Llc | Systems and methods for anti-PAX8 antibodies |
| US20130058926A1 (en) * | 2011-08-30 | 2013-03-07 | Shiseido Company, Ltd. | Method for alleviating and/or preventing skin reddening |
| US10316103B1 (en) | 2012-03-30 | 2019-06-11 | Biocare Medical, Llc | Systems and methods for anti-Uroplakin III antibodies |
| US9494597B2 (en) * | 2012-04-02 | 2016-11-15 | Ab Biosciences, Inc. | Human control antibodies and uses therefor |
| CA2872908C (en) | 2012-05-10 | 2023-11-14 | Gerhard Frey | Multi-specific monoclonal antibodies |
| US9429577B2 (en) | 2012-09-27 | 2016-08-30 | Biocare Medical, Llc | Anti-uroplakin II antibodies systems and methods |
| WO2014100220A2 (en) | 2012-12-18 | 2014-06-26 | Biocare Medical, Llc | Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer |
| RU2681994C2 (ru) * | 2012-12-26 | 2019-03-14 | Онкосинерджи, Инк. | КОМПОЗИЦИИ АНТИТЕЛА К ИНТЕГРИНУ β1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| CA2898239A1 (en) | 2013-01-23 | 2014-07-31 | Syddansk Universitet | Mfap4 binding antibodies blocking the interaction between mfap4 and integrin receptors |
| WO2014122144A1 (en) * | 2013-02-05 | 2014-08-14 | Engmab Ag | BISPECIFIC ANTIBODIES AGAINST CD3ε AND BCMA |
| EP2962113B1 (en) | 2013-02-28 | 2019-04-03 | Biocare Medical, LLC | Anti-p40 antibodies systems and methods |
| DK3052522T3 (da) | 2013-10-03 | 2020-02-24 | Biocare Medical Llc | Anti-sox 10 antistofsystemer og -fremgangsmåder |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| KR102799807B1 (ko) | 2015-12-30 | 2025-04-24 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| CN108693004B (zh) * | 2018-05-24 | 2020-08-04 | 中国农业科学院农业质量标准与检测技术研究所 | 一种检测菜籽粕中是否掺杂抗生素滤渣的方法 |
| MX2020013606A (es) | 2018-06-14 | 2021-05-27 | Bioatla Inc | Constructos de anticuerpos multiespecificos. |
| CA3135836A1 (en) * | 2019-04-01 | 2020-10-08 | Lakepharma, Inc. | Btla-binding (cd272) antibodies for modulating immune response and treating disease |
| US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CN114688461B (zh) * | 2020-12-31 | 2025-02-28 | 青岛海尔施特劳斯水设备有限公司 | 一种漏水检测方法及系统 |
| CN113133431A (zh) * | 2021-02-25 | 2021-07-20 | 中南大学 | 慢性高眼压合并长眼轴动物模型的建立方法、模型及应用 |
| CN114073996B (zh) * | 2021-11-24 | 2023-04-14 | 中山大学 | 一种嵌套式微井阵列芯片及其制备方法 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5540933A (en) * | 1985-05-31 | 1996-07-30 | La Jolla Cancer Research Foundation | Isolation and use of fibronectin receptor |
| EP0330506A3 (en) | 1988-02-26 | 1990-06-20 | Dana Farber Cancer Institute | Vla proteins |
| US20020146410A1 (en) | 1992-05-22 | 2002-10-10 | Helmut Eckert | Monoclonal antibodies and their use |
| US5981478A (en) | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
| US5627263A (en) | 1993-11-24 | 1997-05-06 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
| SI0719859T1 (en) * | 1994-12-20 | 2003-12-31 | Merck Patent Gmbh | Anti-alpha V-integrin monoclonal antibody |
| DE69930723T2 (de) | 1998-01-23 | 2006-11-16 | Merck Patent Gmbh | Verwendung des antikörpers 271.14d9.f8 (dsm acc2331) um die bindung zwischen alphavbeta6-integrin und fibronectin in vitro zu hemmen |
| US6852318B1 (en) * | 1998-05-08 | 2005-02-08 | The Regents Of The University Of California | Methods for detecting and inhibiting angiogenesis |
| ES2322723T5 (es) | 1998-05-08 | 2013-03-11 | The Regents Of The University Of California | Métodos para detectar e inhibir la angiogénesis |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| GB9909392D0 (en) | 1999-04-24 | 1999-06-23 | Imp Cancer Res Tech | Treatment, imaging and diagnosis of disease |
| US20020019330A1 (en) | 1999-08-11 | 2002-02-14 | Richard Murray | Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators |
| US20040009494A1 (en) | 1999-08-11 | 2004-01-15 | Richard Murray | Novel methods of diagnosis of angiogenesis and other conditions, compositions, and the methods of screening for modulators |
| US20020015970A1 (en) | 1999-08-11 | 2002-02-07 | Richard Murray | Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators |
| WO2001011086A2 (en) | 1999-08-11 | 2001-02-15 | Eos Biotechnology, Inc. | Methods of screening for angiogenesis modulators |
| US20030152926A1 (en) | 1999-08-11 | 2003-08-14 | Eos Biotechnology, Inc. | Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
| US20040259152A1 (en) | 2000-02-22 | 2004-12-23 | Richard Murray | Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases |
| JP2004531249A (ja) | 2001-02-14 | 2004-10-14 | プロテイン デザイン ラブス インコーポレイティド | 血管新生の診断方法、組成物、及び血管新生モジュレータのスクリーニング方法 |
| EP1463928A2 (en) | 2001-04-18 | 2004-10-06 | Protein Design Labs | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
| WO2002098358A2 (en) | 2001-06-04 | 2002-12-12 | Eos Biotechnology, Inc. | Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer |
| US7189507B2 (en) | 2001-06-18 | 2007-03-13 | Pdl Biopharma, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| CA2451465A1 (en) | 2001-06-18 | 2002-12-27 | Eos Biotechnology Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| US20040076955A1 (en) | 2001-07-03 | 2004-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer |
| US20040033495A1 (en) | 2001-08-03 | 2004-02-19 | Eos Biotechnology, Inc. | Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
| US20030124579A1 (en) | 2001-09-05 | 2003-07-03 | Eos Biotechnology, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| US20070042360A1 (en) | 2001-09-17 | 2007-02-22 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| EP1434881A4 (en) | 2001-09-17 | 2005-10-26 | Protein Design Labs Inc | METHOD FOR DIAGNOSIS OF CANCER COMPOSITIONS AND METHOD FOR SCREENING ON CANCER MODULATORS |
| US20030232350A1 (en) | 2001-11-13 | 2003-12-18 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| WO2003042661A2 (en) | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| WO2004001384A2 (en) | 2002-06-25 | 2003-12-31 | The Regents Of The University Of California | Methods for inhibiting angiogenesis, cell migration, cell adhesion, and cell survival |
| JP4667873B2 (ja) | 2002-07-16 | 2011-04-13 | アベンティス・ファーマシューティカルズ・インコーポレイテッド | α５β１およびその細胞生存経路を調節する能力 |
| US7276589B2 (en) * | 2002-11-26 | 2007-10-02 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
| US20040253606A1 (en) | 2002-11-26 | 2004-12-16 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
| US7285268B2 (en) * | 2002-11-26 | 2007-10-23 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
| NZ540562A (en) * | 2002-11-26 | 2008-04-30 | Pdl Biopharma Inc | Therapeutic chimeric and humanized antibodies directed against alpha5beta1 integrin, methods for purification of these antibodies, and their use in treating conditions comprising undesirable tissue angiogenesis |
| JP2007524605A (ja) | 2003-04-03 | 2007-08-30 | ピーディーエル バイオファーマ，インコーポレイティド | インテグリンα５β１のインヒビターおよび組織顆粒化の制御のためのそれらの使用 |
| US7662384B2 (en) * | 2004-03-24 | 2010-02-16 | Facet Biotech Corporation | Use of anti-α5β1 antibodies to inhibit cancer cell proliferation |
| US20060008415A1 (en) | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
| EP1819359B1 (en) | 2004-12-09 | 2015-03-18 | Janssen Biotech, Inc. | Anti-integrin immunoconjugates, methods of their production and their use |
| EP1957476A1 (en) | 2005-11-23 | 2008-08-20 | AstraZeneca AB | L-alanine derivatives |
| WO2007060408A2 (en) | 2005-11-23 | 2007-05-31 | Astrazeneca Ab | L-phenylalanine derivatives and their use as integrin antagonists |
| US20090203663A1 (en) | 2006-02-09 | 2009-08-13 | Astrazeneca Ab | Chemical compounds |
| PT1989231E (pt) * | 2006-03-21 | 2015-09-18 | Genentech Inc | Terapêutica combinatória que envolve antagonistas alfa5beta1 |
| AU2007253586A1 (en) | 2006-05-24 | 2007-11-29 | Bayer Schering Pharma Aktiengesellschaft | High affinity human and humanized anti-alpha5beta1 integrin function blocking antibodies with reduced immunogenicity |
| AU2008304452B2 (en) | 2007-09-26 | 2014-01-16 | Genentech, Inc. | Novel antibodies |
| WO2009100110A1 (en) | 2008-02-05 | 2009-08-13 | Medarex, Inc. | Alpha 5 - beta 1 antibodies and their uses |
-
2008
- 2008-09-25 AU AU2008304452A patent/AU2008304452B2/en not_active Ceased
- 2008-09-25 MY MYPI20101284 patent/MY151191A/en unknown
- 2008-09-25 JP JP2010527128A patent/JP2011501656A/ja active Pending
- 2008-09-25 NZ NZ584838A patent/NZ584838A/xx not_active IP Right Cessation
- 2008-09-25 BR BRPI0816049A patent/BRPI0816049A2/pt not_active IP Right Cessation
- 2008-09-25 DK DK08834260.5T patent/DK2200700T3/en active
- 2008-09-25 MX MX2010003325A patent/MX2010003325A/es active IP Right Grant
- 2008-09-25 EP EP08834260.5A patent/EP2200700B1/en active Active
- 2008-09-25 TW TW097136935A patent/TWI547503B/zh not_active IP Right Cessation
- 2008-09-25 CN CN200880117702.0A patent/CN101888878B/zh not_active Expired - Fee Related
- 2008-09-25 CA CA2698609A patent/CA2698609A1/en not_active Abandoned
- 2008-09-25 HR HRP20160308TT patent/HRP20160308T1/hr unknown
- 2008-09-25 CL CL2008002856A patent/CL2008002856A1/es unknown
- 2008-09-25 PE PE2008001669A patent/PE20091029A1/es not_active Application Discontinuation
- 2008-09-25 HU HUE08834260A patent/HUE027911T2/en unknown
- 2008-09-25 US US12/237,640 patent/US7973138B2/en not_active Expired - Fee Related
- 2008-09-25 KR KR1020107006513A patent/KR20100065162A/ko not_active Abandoned
- 2008-09-25 WO PCT/US2008/077622 patent/WO2009042746A1/en not_active Ceased
- 2008-09-25 AR ARP080104170A patent/AR066170A1/es unknown
- 2008-09-25 RU RU2010116184/10A patent/RU2490277C2/ru not_active IP Right Cessation
- 2008-09-25 SI SI200831589T patent/SI2200700T1/sl unknown
-
2010
- 2010-03-19 CO CO10033130A patent/CO6260094A2/es active IP Right Grant
-
2011
- 2011-05-20 US US13/112,833 patent/US9284376B2/en not_active Expired - Fee Related
- 2011-05-20 US US13/112,839 patent/US8840887B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011501656A5 (enExample) | ||
| CN112646031B (zh) | 抗4-1bb纳米抗体及其用途 | |
| US12377144B2 (en) | Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen | |
| DK2493503T3 (en) | DOSAGE SCHEDULE FOR THE ADMINISTRATION OF A CD19xCD3 bispecific antibody | |
| AU2011336650B2 (en) | Chimeric rabbit/human ROR1 antibodies | |
| TW201023855A (en) | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan | |
| JP2009536921A5 (enExample) | ||
| JP2012521218A5 (enExample) | ||
| JP2017522861A5 (enExample) | ||
| EP3008093A1 (en) | Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer | |
| RU2013108054A (ru) | Антитела против а2 тенасцина с и способы их применения | |
| WO2019137397A1 (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| US10519246B2 (en) | Anti-fibroblast activation protein (FAP) antibodies for treatment and diagnosis | |
| TWI879889B (zh) | 用於分子接合或工程化的縱排重複癌症靶向胜肽及其於癌症診療中的用途 | |
| IL297619A (en) | Use of a multimeric anti-dr5 binding compound in combination with cancer therapy for the treatment of cancer | |
| CN107614530A (zh) | 用于多发性骨髓瘤（mm）的治疗 | |
| WO2021047386A1 (zh) | 靶向caix抗原的纳米抗体及其应用 | |
| CN109265547A (zh) | 一种抗cd47抗体及其应用 | |
| JP2024054123A (ja) | 癌の治療のための配合剤 | |
| CN106164094A (zh) | 双特异性抗原结合多肽 | |
| CN111825766B (zh) | 抗il-4r单域抗体及其应用 | |
| WO2023143535A1 (zh) | 一种靶向il-18bp的抗体及其应用 | |
| EP4435006A1 (en) | Bispecific antibody and use thereof | |
| US20250109206A1 (en) | Activatable bispecific anti-cd3 and anti-pd-l1 proteins and uses thereof | |
| RU2761638C1 (ru) | Антитела против лиганда программируемой смерти (pd-l1) и их применение |